-
Pomalidomide Enhances CAR-T Therapy Effectiveness in Hematological Malignancies: A Promising Synergy
Relapsed and refractory multiple myeloma (R/R MM) and B-cell leukemia/lymphoma with extramedullary disease (EMD) represent some of the most formidable challenges in hematology. These conditions often carry a bleak prognosis due to their resistance to conventional therapies and the complex nature of extramedullary disease, where cancer cells spread outside the bone marrow. Chimeric antigen receptor…
-
Interview with Dr. Swaminathan P iyer at the EHA 2024: Exploring Breakthroughs in Secondary HLH Treatment with ELA26
At this year’s European Hematology Association (EHA) conference, we had the opportunity to speak with Dr. Swaminathan P iyer, Professor of Medicine at MD Anderson Cancer Center, about the groundbreaking phase I study on ELA26 for secondary hemophagocytic lymphohistiocytosis (HLH). Dr. Iyer shared the promising data from the treatment-naive cohort, which showed a remarkable 100%…
-
Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study
In April 2024, the journal Blood Science published an important study led by Dr. Gang An and colleagues from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, investigating the use of subcutaneous daratumumab in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). Multiple myeloma is…
-
Dr. Lai Wei: Interpretation of Key Points from the 2024 Edition of the Chinese Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic
Hepatology Digest: Metabolic-associated fatty liver disease (MAFLD) is one of the most prevalent liver diseases globally, posing a severe threat and burden. Can you discuss the current epidemiological status of…
-
Insights from Dr. Khalil Ghanem on the Challenges and Future of Syphilis Diagnosis, Treatment, and Prevention
Infectious Disease Frontier: Neurosyphilis is one of the most severe clinical forms of syphilis. What are the challenges in the diagnosis and treatment of Neurosyphilis? Dr. Khalil Ghanem: The main…
-
Application of carbapenems in the treatment of MDR-GNB and management of drug resistance
Infectious Disease Frontier: Could you share the unique advantages of Carbapenem antibiotics in treating multi-drug resistant Gram-negative infections, and do these advantages justify their use as a first-line treatment? Dr.…
-
Breaking the Barrier of Immunotherapy Consolidation, ALK-TKI Combined with CRT Might Transform the Standard Treatment for Unresectable ALK-Positive
The American Society for Radiation Oncology (ASTRO) Annual Meeting took place in Washington, D.C., from September 29,2024 to October 2,2024. As one of the most prestigious annual events in radiation oncology, ASTRO offers a platform to share the latest advances, focusing on radiotherapy as a primary treatment for various cancers, alongside key updates in technology…
-
Dr. Lorusso comments on the OS results of KEYNOTE-A18 study: There is a new standard for the treatment of locally advanced high-risk cervical cancer
The data of the KEYNOTE-A18 study disclosed at the Presidential Symposium I of the 2024 ESMO Congress shows that the overall survival (OS) of newly diagnosed patients with locally advanced cervical cancer who received pembrolizumab and concurrent chemoradiotherapy (CRT) is significantly improved (abstract number 709O). The 36-month OS rate of pembrolizumab + concurrent CRT treatment…
Connecting Medical Expertise through Media